Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Non-Seminomatous Germ Cell Tumour (NSGCT)
dc.contributor.author | Ariffin, Nur A | |
dc.contributor.author | Nason, Gregory J | |
dc.contributor.author | Omer, Shawgi I | |
dc.contributor.author | Considine, Shane W | |
dc.contributor.author | Sweeney, Paul | |
dc.contributor.author | Power, Derek G | |
dc.date.accessioned | 2017-12-18T14:58:28Z | |
dc.date.available | 2017-12-18T14:58:28Z | |
dc.date.issued | 2017-11 | |
dc.identifier.uri | http://hdl.handle.net/10147/622702 | |
dc.description.abstract | Testicular cancer is the most common neoplasm in 20- to 35-year-old men and accounts for one percent of all male neoplasms1,2. It has an incidence of 6.2 per 100,000 per year and an overall mortality of 0.3 deaths per 100,000 per year in the Irish male population3. It is also one of the most curable malignant conditions and has become a model for the multimodal management of malignancies4. Metastases from testicular cancer follow a predictable path via lymphatic spread to the retroperitoneal lymph nodes5. The primary treatment of nodal disease is platinum-based chemotherapy. Twenty to fifty percent of patients have metastatic disease after chemotherapy, in the form of significant residual retroperitoneal disease. In this subset of patients, surgical resection of the residual disease burden plays an important part. | |
dc.language.iso | en | en |
dc.publisher | Irish Medical Journal | en |
dc.subject | TESTICULAR CANCER | en |
dc.subject | CHEMOTHERAPY | en |
dc.title | Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Non-Seminomatous Germ Cell Tumour (NSGCT) | en |
dc.type | Article | en |
dc.identifier.journal | Irish Medical Journal | en |
dc.description.funding | No funding | en |
dc.description.province | Leinster | en |
dc.description.peer-review | peer-review | en |
html.description.abstract | Testicular cancer is the most common neoplasm in 20- to 35-year-old men and accounts for one percent of all male neoplasms1,2. It has an incidence of 6.2 per 100,000 per year and an overall mortality of 0.3 deaths per 100,000 per year in the Irish male population3. It is also one of the most curable malignant conditions and has become a model for the multimodal management of malignancies4. Metastases from testicular cancer follow a predictable path via lymphatic spread to the retroperitoneal lymph nodes5. The primary treatment of nodal disease is platinum-based chemotherapy. Twenty to fifty percent of patients have metastatic disease after chemotherapy, in the form of significant residual retroperitoneal disease. In this subset of patients, surgical resection of the residual disease burden plays an important part. |
Files in this item
This item appears in the following Collection(s)
-
Children's Health Ireland (CHI) at Crumlin
Formerly Our Lady's Children's Hospital Crumlin